Efficacy and Safety of Bariatric Surgery in Acquired Hypothalamic Obesity: A Systematic Review and Individual Patient Data Meta-Analysis.

Obes RevJun 22, 2026 (epub)
Clinical ResearchEndocrinologyGeneral SurgeryOpen access

Johannes Fessler, Pauline Faucher, Christine Poitou et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and individual patient data meta-analysis evaluated the efficacy and safety of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in adults with acquired hypothalamic obesity (HO). The analysis included 36 patients and found a percent total weight loss of 16.5% after a median follow-up of 31.5 months. Both surgical options showed similar outcomes.

Key findings

  • Percent total weight loss after surgery was 16.5% (95% CI, 11.6%-21.4%; p = 5.7 × 10 -8).
  • Weight loss after RYGB was 17.4% compared to 15.2% after SG, though not significantly different.
  • Patients with HO experienced a 12.5%-point lower weight loss compared to those with common obesity.

Why it matters

Understanding the outcomes of bariatric surgery in patients with acquired hypothalamic obesity is crucial, as these patients may have different weight loss trajectories compared to those with common obesity. This knowledge can inform clinical decision-making and patient management.

Source

PubMed · PMID 42331400Free full text on PubMed Central

Published in Obes Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.